Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344706 | 0.87 | BRD4 (0.67) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL21903057 | 0.85 | SMN1; SMN2 (0.60) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL5350551 | 0.85 | RAB9A (0.76) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL29818326 | 0.80 | HPGD (0.68) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL31396768 | 0.80 | HPGD (0.68) | KMT2AMEN1ALDH1A1RAB9AHPGD | |
| SCHEMBL7145756 | 0.80 | MMP13 (0.59) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL9416645 | 0.79 | MMP13 (0.94) | KMT2AMEN1ALDH1A1HPGDMMP13 | |
| SCHEMBL2234130 | 0.78 | HPGD (1.00) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL7938316 | 0.78 | HPGD (0.56) | KMT2AMEN1ALDH1A1RAB9AHPGD | |
| SCHEMBL2922655 | 0.78 | MMP13 (0.81) | KMT2AMEN1ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322642-B1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of Protein Jun-kinases | MERCK SERONO SA (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-7544700-B2 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein JunKinases | LABORATOIRES SERONO SA (CH) | 2009-06-09 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| EP-1675844-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | Sterix Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2005-10-13 | — | — | US | disclosed |
| WO-2005042513-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | STERIX LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| US-20040077854-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases | MERCK SERONO SA (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1322642-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | Applied Research Systems ARS Holding N.V. (AN) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026733-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-04 | — | — | WO | disclosed |
| EP-1193268-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases | Applied Research Systems ARS Holding N.V. (AN) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077854-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases | MAPK1, MAP3K1, MAPKAPK2 | KMT2A 1159/4885MEN1 2351/4885ALDH1A1 1726/4885 |
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD17B3 | KMT2A 1973/4885MEN1 2978/4885ALDH1A1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.